Salute e Benessere
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
There was an exceptionally strong vote turnout at the 2023 Annual Meeting, with 961.7 million votes cast out of the total 1.2 billion shares outstanding as of the record date, comprising over 77% of all common and preferred shares outstanding. This vote turnout repeated the exceptional turnout at the 2022 Annual Meeting, where 841 million votes were cast comprising 78% of the total shares that were then outstanding.
There were 5 Proposals for shareholders to decide at the 2023 Annual Meeting, and all of them were approved by shareholders with overwhelming margins. The votes were as follows:
Proposal 1: Re-Election of Class I Directors for a new 3-year term
Proposal 2: Ratification of Appointment of Independent Auditor – Cherry Bekaert
Proposal 3: Ratification of Stock Options awarded to Management in 2020.
Proposal 4: Ratification of Stock Options Awarded to Non-Executive Directors in 2020.
Proposal 5: Approval, on an advisory basis, of executive compensation in 2023.
During the Annual Meeting, the Company also conducted an informal discussion session that was publicly available by audio link to all interested parties. An audio recording has also been posted on the Company's website and will remain available there through Sunday, July 7 , 2024.
During the discussion session, the Company reviewed its strong progress since the last Annual Meeting and described its plans and priorities, and its many growth opportunities, going forward. The Company's descriptions of plans and opportunities were subject to standard cautions about forward looking statements and related uncertainties and risks.
"We are excited about the Company's progress on many fronts over the last 18 months, including in regard to the Marketing Authorization Application (MAA) in the UK, the Sawston facility, the Flaskworks system, the Company's intellectual property portfolio and collaborations, the Company's lawsuit against parties whom the Company believes have been manipulating the Company's stock, and other matters," commented Linda Powers , the Company's CEO.
"We are especially grateful for the ongoing strong support from our shareholders, as reflected in the exceptional voting results of the Annual Meeting."
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program involves DCVax -L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The Company has also developed DCVax -Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania .
View original content: https://www.prnewswire.co.uk/news-releases/northwest-biotherapeutics-announces-positive-votes-at-annual-meeting-reviews-strong-progress-and-growth-opportunities-302189074.html